Dechert Advises Abivax on €85 Million New Financing  

July 28, 2021

Dechert, a global law firm with a leading life sciences practice, advised Abivax, a Euronext Paris listed clinical-stage biotechnology company, in connection with its oversubscribed capital increase of €60 million and convertible bonds of €25 million, totalling €85 million in new financing.

The proceeds of the transaction will be used for the further advancement of clinical programs in chronic inflammatory diseases, and for expanding the biotech cash runway into Q2 2022.

The Dechert team included Paris partner Alain Decombe, London partner Patrick Lyons, Paris associates Benhouda Derradji and Vianney Toulouse and London associate Nick Quarrie.

Translate page into French.

About Dechert

Dechert is a global law firm with 23 offices around the world. We handle cases and transactions with high strategic stakes, bringing energy, creativity and responsiveness. Our clients choose us because of our pragmatic, business-focused approach to their legal issues.

The Dechert team in France has 75 lawyers focused on Corporate and Securities, Finance, Antitrust, Public Law, Regulatory, Intellectual Property, International Arbitration, Complex Commercial Litigation, White Collar Crime, Tax and Social Law, Financial Services and Asset Management.

Subscribe to Dechert Updates